Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.

IF 1.6 4区 医学 Q2 Medicine
Acta Clinica Belgica Pub Date : 2024-06-01 Epub Date: 2024-07-31 DOI:10.1080/17843286.2024.2381272
Myriam Drysdale, Thor Hautekiet, Moushmi Singh, Joris Hautekiet, Linda Ludikhuyze, Vishal Patel, Daniel C Gibbons, Dorothée De Roeck, Kirsten Colpaert, Emily J Lloyd, Eva Van Braeckel
{"title":"Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.","authors":"Myriam Drysdale, Thor Hautekiet, Moushmi Singh, Joris Hautekiet, Linda Ludikhuyze, Vishal Patel, Daniel C Gibbons, Dorothée De Roeck, Kirsten Colpaert, Emily J Lloyd, Eva Van Braeckel","doi":"10.1080/17843286.2024.2381272","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease.</p><p><strong>Methods: </strong>This was a multicentric, single-arm observational cohort study of non-hospitalised patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022 at nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalisations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab.</p><p><strong>Results: </strong>A total of 634 patients were included (63.4% aged < 65 years; 50.3% male). A high proportion (67.7%; <i>n</i> = 429/634) of patients were immunocompromised, with 36.9% (<i>n</i> = 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% (<i>n</i> = 79/634) of sotrovimab-treated patients were hospitalised due to any cause (median duration 4 days; median time to hospitalisation 14 days) and 1.1% (<i>n</i> = 7/634) died due to any cause. The proportion of sotrovimab-treated patients experiencing COVID-19-related hospitalisation was highest during the Delta predominance and Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalisations were consistently low (all ≤2.7%).</p><p><strong>Conclusion: </strong>This study indicated low rates of COVID-19-related hospitalisations and all-cause deaths in sotrovimab-treated patients in Belgium, including during Omicron subvariant periods, despite over two-thirds of the study population being immunocompromised.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2024.2381272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease.

Methods: This was a multicentric, single-arm observational cohort study of non-hospitalised patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022 at nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalisations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab.

Results: A total of 634 patients were included (63.4% aged < 65 years; 50.3% male). A high proportion (67.7%; n = 429/634) of patients were immunocompromised, with 36.9% (n = 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% (n = 79/634) of sotrovimab-treated patients were hospitalised due to any cause (median duration 4 days; median time to hospitalisation 14 days) and 1.1% (n = 7/634) died due to any cause. The proportion of sotrovimab-treated patients experiencing COVID-19-related hospitalisation was highest during the Delta predominance and Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalisations were consistently low (all ≤2.7%).

Conclusion: This study indicated low rates of COVID-19-related hospitalisations and all-cause deaths in sotrovimab-treated patients in Belgium, including during Omicron subvariant periods, despite over two-thirds of the study population being immunocompromised.

比利时接受索托维单抗治疗以防止病情恶化为重症 COVID-19 的患者特征和疗效。
目的:索托维单抗是一种双效工程化人类单克隆抗体,已被证实可显著降低COVID-19高危患者的住院和死亡风险。在此,我们描述了比利时在德尔塔波和欧米克隆波期间索托维单抗治疗在COVID-19高危重症患者中的实际使用情况和效果:这是一项多中心、单臂观察性队列研究,研究对象是2021年11月1日至2022年8月2日期间在比利时九家医院接受索托维单抗门诊治疗的非住院患者。研究的主要结果是在首次使用索特罗维奇单抗后的29天急性随访期内的全因住院、COVID-19相关住院和全因死亡:共纳入634名患者,其中63.4%(n=429/634)的患者免疫力低下,36.9%(n=234/634)的患者正在接受恶性肿瘤治疗。在为期29天的急性期,12.5%(n = 79/634)的索曲单抗治疗患者因任何原因住院(中位持续时间为4天;中位住院时间为14天),1.1%(n = 7/634)的患者因任何原因死亡。索托维单抗治疗的患者因COVID-19相关住院的比例在Delta优势期和Delta/BA.1共显性期最高(均为6.3%)。在BA.1优势期、BA.1/BA.2共显性期和BA.2/BA.5共显性期,COVID-19相关住院率一直较低(均≤2.7%):这项研究表明,在比利时,索托维单抗治疗患者的COVID-19相关住院率和全因死亡率较低,包括在Omicron子变异期,尽管研究人群中有三分之二以上的人免疫力低下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信